Vita Life Sciences Limited (ASX:VLS)
Australia · Delayed Price · Currency is AUD 2.780
+0.040 (1.46%)
Aug 21, 2026, 4:10 PM AEST
Vita Life Sciences Ratios and Metrics
Market cap in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 157 | 141 | 111 | 96 | 77 | 105 | |
Market Cap Growth | 28.87% | 26.53% | 16.19% | 25.14% | -26.95% | 93.88% |
Enterprise Value | 125 | 114 | 84 | 77 | 62 | 89 |
Last Close Price | 2.78 | 2.48 | 1.83 | 1.56 | 1.14 | 1.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.07 | 13.51 | 12.68 | 10.56 | 10.81 | 12.65 |
Forward PE | - | 16.81 | 16.81 | 16.81 | 16.81 | 16.81 |
PS Ratio | 1.63 | 1.51 | 1.40 | 1.31 | 1.15 | 1.84 |
PB Ratio | 2.81 | 2.51 | 2.13 | 2.21 | 2.10 | 3.45 |
P/TBV Ratio | 2.81 | 2.51 | 2.13 | 2.21 | 2.10 | 3.41 |
P/FCF Ratio | 10.72 | 8.89 | 18.70 | 7.78 | 29.06 | 18.29 |
P/OCF Ratio | 10.60 | 8.58 | 18.09 | 7.38 | 27.60 | 17.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.30 | 1.22 | 1.06 | 1.06 | 0.93 | 1.57 |
EV/EBITDA Ratio | 7.63 | 7.81 | 6.99 | 6.39 | 5.66 | 7.94 |
EV/EBIT Ratio | 8.17 | 8.08 | 7.20 | 6.53 | 5.79 | 8.11 |
EV/FCF Ratio | 8.55 | 7.17 | 14.10 | 6.29 | 23.57 | 15.58 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.01 | 0.01 | 0.02 | 0.01 |
Debt / EBITDA Ratio | 0.13 | 0.16 | 0.04 | 0.03 | 0.05 | 0.03 |
Debt / FCF Ratio | 0.15 | 0.15 | 0.09 | 0.03 | 0.23 | 0.07 |
Net Debt / Equity Ratio | -0.57 | -0.59 | -0.54 | -0.56 | -0.41 | -0.51 |
Net Debt / EBITDA Ratio | -1.99 | -2.28 | -2.34 | -2.00 | -1.37 | -1.38 |
Net Debt / FCF Ratio | -2.16 | -2.09 | -4.71 | -1.97 | -5.72 | -2.71 |
Asset Turnover | 1.24 | 1.21 | 1.21 | 1.32 | 1.38 | 1.35 |
Inventory Turnover | 2.44 | 2.29 | 2.33 | 2.34 | 2.03 | 2.42 |
Quick Ratio | 2.10 | 2.04 | 2.11 | 2.21 | 1.66 | 1.59 |
Current Ratio | 2.82 | 2.73 | 3.06 | 2.98 | 2.77 | 2.43 |
Return on Equity (ROE) | 20.58% | 19.23% | 18.36% | 22.74% | 21.94% | 30.06% |
Return on Assets (ROA) | 12.34% | 11.40% | 11.06% | 13.30% | 13.82% | 16.32% |
Return on Invested Capital (ROIC) | 44.91% | 43.07% | 37.40% | 42.75% | 40.39% | 60.21% |
Return on Capital Employed (ROCE) | 26.60% | 24.20% | 22.20% | 27.20% | 29.00% | 35.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.12% | 7.41% | 7.89% | 9.47% | 9.25% | 7.91% |
FCF Yield | 9.33% | 11.25% | 5.35% | 12.86% | 3.44% | 5.47% |
Dividend Yield | 5.04% | 5.63% | 5.47% | 5.76% | 5.24% | 3.69% |
Payout Ratio | 68.56% | 58.26% | 58.85% | 37.08% | 42.88% | 34.91% |
Buyback Yield / Dilution | -0.41% | -2.27% | -1.70% | -1.30% | -1.64% | -0.97% |
Total Shareholder Return | 4.63% | 3.37% | 3.77% | 4.46% | 3.60% | 2.73% |